Skip to main content
Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · AUPH ISIN · CA05156V1022 LEI · 5299008YP2BW4570ML28 US Manufacturing
Open in API
Filings indexed 582 across all filing types
Latest filing 2016-12-19 Regulatory Filings
Country CA Canada
Listing US AUPH

About Aurinia Pharmaceuticals Inc.

https://www.auriniapharma.com

Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering therapies for patients with severe autoimmune diseases that have high unmet medical needs. The company's principal product is LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus. Aurinia's research and development efforts are centered on immunomodulating therapies for various autoimmune and kidney-related diseases.

Recent filings

Filing Released Lang Actions
AURINIA PHARMACEUTICALS INC. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Aurinia Pharmaceuticals Inc., which is a report of a foreign private issuer pursuant to SEC rules. It includes a news release about a long-term manufacturing collaboration agreement. The document length is 2373 characters, which is relatively short and primarily serves as an announcement rather than a detailed report. There are no financial statements or substantive financial data included. The document is not an annual or interim report, earnings release, or any detailed financial or management report. It is a regulatory filing providing an update on a corporate event. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2016-12-19 English
AURINIA PHARMACEUTICALS INC. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Aurinia Pharmaceuticals Inc., which is a report of a foreign private issuer pursuant to SEC rules. It includes a news release about receipt of FDA End of Phase 2 meeting minutes. The document is relatively short (2309 characters) and primarily serves as a regulatory filing to inform the SEC and investors about a specific event or update. It does not contain detailed financial statements, management discussion, or comprehensive report content. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other specific categories.
2016-12-13 English
AURINIA PHARMACEUTICALS INC. 6-K
Board/Management Information Classification · 95% confidence The document is a Form 6-K filed by Aurinia Pharmaceuticals Inc., which is a report of a foreign private issuer pursuant to SEC rules. The content includes a signature by the CFO and an exhibit index referencing a news release about a board appointment. The document length is 2141 characters, which is relatively short and does not contain detailed financial data or comprehensive reports. The main content is an announcement of a board member appointment, which fits the category of Board/Management Information. It is not an annual report, earnings release, or other financial report. Therefore, the appropriate classification is Board/Management Information (MANG).
2016-12-12 English
AURINIA PHARMACEUTICALS INC. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Aurinia Pharmaceuticals Inc., with the SEC. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Forms 20-F or 40-F. The document includes a news release about clinical study data but does not contain comprehensive financial statements or detailed financial analysis. The length is only 2404 characters, which is quite short and typical for a regulatory announcement rather than a full report. There is no indication that this is an annual report, interim report, earnings release, or any other detailed financial filing. The document is primarily a regulatory filing to disclose material information to the SEC and investors. Therefore, the appropriate classification is Regulatory Filings (RNS).
2016-11-21 English
AURINIA PHARMACEUTICALS INC. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Aurinia Pharmaceuticals Inc., which is a report of a foreign private issuer pursuant to SEC rules under the Securities Exchange Act of 1934. The text includes standard Form 6-K headings, signature, and an exhibit index referencing a news release about a clinical study. The document length is 2386 characters, which is relatively short and does not contain detailed financial statements or comprehensive financial analysis. It is a regulatory filing used to report material information between annual reports for foreign issuers. Therefore, this document fits the category of Regulatory Filings (RNS) as it does not contain a full annual report, interim report, or other specific report types but is a general SEC filing for foreign issuers.
2016-11-16 English
AURINIA PHARMACEUTICALS INC. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Aurinia Pharmaceuticals Inc., which is a report of a foreign private issuer pursuant to SEC rules. It includes a news release about a presentation at a healthcare conference. The document length is only 2107 characters, indicating it is a short filing. It does not contain detailed financial statements or substantive financial data, but rather an announcement of an event (presentation at a conference). According to the classification rules, Form 6-K filings that provide updates or announcements without detailed financial data typically fall under Regulatory Filings (RNS). The document is not an annual report, earnings release, or other detailed financial report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2016-11-10 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.